Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

FDA Approves New Lilly Diabetes Treatment

Friday, May 13, 2022 04:25 PM EDT
By Alex Brown
(photo courtesy: Eli Lilly & Co.)

The U.S. Food and Drug Administration has approved a new drug from Eli Lilly and Co. (NYSE: LLY) to treat type 2 diabetes that is also shown to help with weight loss. The FDA says Mounjaro “was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.”

Mounjaro, also known as tirzepatide, is a once-weekly injection treatment designed to activate the GLP-1 and GIP receptors, which are hormones that lead to improved blood sugar control.

“Given the challenges many patients experience in achieving their target blood sugar goals, today’s approval of Mounjaro is an important advance in the treatment of type 2 diabetes,” said Dr. Patrick Archdeacon, associate director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA’s Center for Drug Evaluation and Research.

According to our partners at the Indianapolis Business Journal, Lilly is also studying the use of Mounjaro to treat obesity, though it has not yet submitted the drug to the FDA for such use.

In its announcement Friday, however, the FDA said obesity was common among participants involved in the study of Mounjaro. The patients who received the maximum recommended dose saw an average weight loss of 15 pounds more than placebo when neither were used with insulin and 23 pounds more than placebo with both were used with insulin.

The IBJ reports Lilly has not yet said how much it will charge for the drug once it’s available.

Story Continues Below

Most Popular Stories

Perspectives

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

Navigating Indiana’s policy landscape: A personal perspective on Dentons LegCon

In the hustle and bustle of our professional lives, we often find ourselves engrossed in the intricacies of our trades. However, amidst our daily routines, there exists a unique opportunity to broaden our horizons and delve into the critical issues facing the state of Indiana. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service